The American Society of Hematology annual meeting helped set the stage for what could be the first chimeric antigen receptor T-cell (CAR-T) therapies approved in the US with Kite Pharma Inc. maintaining its spot as a leader in the field, while Juno Therapeutics Inc. continues to face questions about safety.
Kite’s latest data from the ZUMA-1 clinical trial, which is expected to support US FDA approval of the CAR-T therapy...